JP2015501817A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501817A5 JP2015501817A5 JP2014546152A JP2014546152A JP2015501817A5 JP 2015501817 A5 JP2015501817 A5 JP 2015501817A5 JP 2014546152 A JP2014546152 A JP 2014546152A JP 2014546152 A JP2014546152 A JP 2014546152A JP 2015501817 A5 JP2015501817 A5 JP 2015501817A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- targeting sequence
- pharmaceutical composition
- composition according
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161568590P | 2011-12-08 | 2011-12-08 | |
| US61/568,590 | 2011-12-08 | ||
| PCT/US2012/068609 WO2013086444A2 (en) | 2011-12-08 | 2012-12-07 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017041744A Division JP6581132B2 (ja) | 2011-12-08 | 2017-03-06 | ヒトｌｍｎａを標的とするオリゴヌクレオチド類似体を使用する早老性ラミノパシーを処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501817A JP2015501817A (ja) | 2015-01-19 |
| JP2015501817A5 true JP2015501817A5 (2) | 2016-01-28 |
| JP6132849B2 JP6132849B2 (ja) | 2017-05-31 |
Family
ID=47429038
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546150A Active JP6132848B2 (ja) | 2011-12-08 | 2012-12-07 | ヒトｌｍｎａを標的とするオリゴヌクレオチド類似体 |
| JP2014546152A Expired - Fee Related JP6132849B2 (ja) | 2011-12-08 | 2012-12-07 | ヒトｌｍｎａを標的とするオリゴヌクレオチド類似体を使用する早老性ラミノパシーを処置するための方法 |
| JP2017041744A Expired - Fee Related JP6581132B2 (ja) | 2011-12-08 | 2017-03-06 | ヒトｌｍｎａを標的とするオリゴヌクレオチド類似体を使用する早老性ラミノパシーを処置するための方法 |
| JP2017041741A Active JP6596032B2 (ja) | 2011-12-08 | 2017-03-06 | ヒトｌｍｎａを標的とするオリゴヌクレオチド類似体 |
| JP2019077698A Pending JP2019129848A (ja) | 2011-12-08 | 2019-04-16 | ヒトｌｍｎａを標的とするオリゴヌクレオチド類似体 |
| JP2019109410A Pending JP2019172691A (ja) | 2011-12-08 | 2019-06-12 | ヒトｌｍｎａを標的とするオリゴヌクレオチド類似体を使用する早老性ラミノパシーを処置するための方法 |
| JP2021065398A Active JP7277503B2 (ja) | 2011-12-08 | 2021-04-07 | ヒトｌｍｎａを標的とするオリゴヌクレオチド類似体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546150A Active JP6132848B2 (ja) | 2011-12-08 | 2012-12-07 | ヒトｌｍｎａを標的とするオリゴヌクレオチド類似体 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017041744A Expired - Fee Related JP6581132B2 (ja) | 2011-12-08 | 2017-03-06 | ヒトｌｍｎａを標的とするオリゴヌクレオチド類似体を使用する早老性ラミノパシーを処置するための方法 |
| JP2017041741A Active JP6596032B2 (ja) | 2011-12-08 | 2017-03-06 | ヒトｌｍｎａを標的とするオリゴヌクレオチド類似体 |
| JP2019077698A Pending JP2019129848A (ja) | 2011-12-08 | 2019-04-16 | ヒトｌｍｎａを標的とするオリゴヌクレオチド類似体 |
| JP2019109410A Pending JP2019172691A (ja) | 2011-12-08 | 2019-06-12 | ヒトｌｍｎａを標的とするオリゴヌクレオチド類似体を使用する早老性ラミノパシーを処置するための方法 |
| JP2021065398A Active JP7277503B2 (ja) | 2011-12-08 | 2021-04-07 | ヒトｌｍｎａを標的とするオリゴヌクレオチド類似体 |
Country Status (16)
| Country | Link |
|---|---|
| US (7) | US9326992B2 (2) |
| EP (3) | EP2788487B1 (2) |
| JP (7) | JP6132848B2 (2) |
| CY (1) | CY1120495T1 (2) |
| DK (1) | DK2788487T3 (2) |
| ES (2) | ES2935606T3 (2) |
| HR (1) | HRP20181022T1 (2) |
| HU (1) | HUE038369T2 (2) |
| LT (1) | LT2788487T (2) |
| PL (1) | PL2788487T3 (2) |
| PT (1) | PT2788487T (2) |
| RS (1) | RS57467B1 (2) |
| SI (1) | SI2788487T1 (2) |
| SM (1) | SMT201800337T1 (2) |
| TR (1) | TR201809173T4 (2) |
| WO (2) | WO2013086441A2 (2) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| KR20200133284A (ko) | 2010-05-28 | 2020-11-26 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| HK1201514A1 (en) | 2011-11-18 | 2015-09-04 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
| ES2935606T3 (es) | 2011-12-08 | 2023-03-08 | Sarepta Therapeutics Inc | Análogos de oligonucleótidos dirigidos a LMNA humana |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US11236338B2 (en) * | 2013-09-05 | 2022-02-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| EA030615B1 (ru) | 2013-12-24 | 2018-08-31 | Сентисс Фарма Прайвет Лимитед | Офтальмологический раствор бримонидина для местного применения |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| AU2016264471B2 (en) * | 2015-05-19 | 2022-01-27 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| MA50829A (fr) * | 2015-06-01 | 2018-04-11 | Sarepta Therapeutics Inc | Exclusion d'exon induite pat technologie antisens dans le collagène de type vii |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| MX2018013157A (es) | 2016-04-29 | 2019-05-23 | Sarepta Therapeutics Inc | Analogos de oligonucleotidos dirigidos a lmna humana. |
| CN110214183A (zh) | 2016-08-03 | 2019-09-06 | 哈佛大学的校长及成员们 | 腺苷核碱基编辑器及其用途 |
| WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| KR102622411B1 (ko) | 2016-10-14 | 2024-01-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| EP3594346A4 (en) * | 2017-03-10 | 2020-12-16 | National Center For Child Health And Development | ANTISENS OLIGONUCLEOTIDE AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF TYPE IA GLYCOGEN STORAGE DISEASE |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| JP7246729B2 (ja) * | 2017-05-18 | 2023-03-28 | 国立大学法人京都大学 | 脊髄小脳変性症３６型の予防又は治療用組成物 |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| KR102398295B1 (ko) * | 2018-03-09 | 2022-05-17 | 다이이찌 산쿄 가부시키가이샤 | 당원병 Ia형 치료약 |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| WO2020051360A1 (en) * | 2018-09-05 | 2020-03-12 | The Broad Institute, Inc. | Base editing for treating hutchinson-gilford progeria syndrome |
| WO2020061497A1 (en) * | 2018-09-20 | 2020-03-26 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of lmna expression |
| US10883084B2 (en) | 2018-10-05 | 2021-01-05 | Xenotherapeutics, Inc. | Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same |
| MX2021003866A (es) | 2018-10-05 | 2021-09-08 | Xenotherapeutics Inc | Productos y metodos de xenotransplante. |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| US12215382B2 (en) | 2019-03-01 | 2025-02-04 | The General Hospital Corporation | Liver protective MARC variants and uses thereof |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| EP3976010A4 (en) * | 2019-06-03 | 2023-08-02 | Quralis Corporation | Oligonucleotides and methods of use for treating neurological diseases |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| AU2020368539A1 (en) | 2019-10-16 | 2022-04-28 | Massachusetts Institute Of Technology | Engineered muscle targeting compositions |
| IL297761A (en) | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence |
| WO2024097822A1 (en) * | 2022-11-02 | 2024-05-10 | Sarepta Therapeutics, Inc. | Formulation of an antisense oligomer conjugate |
| WO2025072672A2 (en) | 2023-09-27 | 2025-04-03 | Judo Bio, Inc. | Slc6a19-targeting modulatory nucleic acid agents |
| WO2025072699A1 (en) | 2023-09-27 | 2025-04-03 | Judo Bio, Inc. | Aminoglycosides for delivery of agents to the kidney |
| WO2025072713A1 (en) | 2023-09-27 | 2025-04-03 | Judo Bio, Inc. | Polymyxins for delivery of agents to the kidney |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
| US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
| US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| WO1986005519A1 (en) | 1985-03-15 | 1986-09-25 | James Summerton | Polynucleotide assay reagent and method |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US4794499A (en) | 1988-02-16 | 1988-12-27 | Ott John N | Grounding device for lamp with shielded electrodes |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| AU659482B2 (en) | 1991-06-28 | 1995-05-18 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
| US7572582B2 (en) | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| WO1999042091A2 (en) | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
| US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
| US7053207B2 (en) | 1999-05-04 | 2006-05-30 | Exiqon A/S | L-ribo-LNA analogues |
| US7070807B2 (en) | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
| WO2001047496A1 (en) | 1999-12-29 | 2001-07-05 | Mixson A James | Histidine copolymer and methods for using same |
| CA2459347C (en) | 2001-09-04 | 2012-10-09 | Exiqon A/S | Locked nucleic acid (lna) compositions and uses thereof |
| KR100464261B1 (ko) | 2002-01-24 | 2005-01-03 | 주식회사 파나진 | Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
| KR20030084444A (ko) | 2002-04-26 | 2003-11-01 | 주식회사 파나진 | Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
| US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
| US7211668B2 (en) | 2003-07-28 | 2007-05-01 | Panagene, Inc. | PNA monomer and precursor |
| WO2007047913A2 (en) * | 2005-10-20 | 2007-04-26 | Isis Pharmaceuticals, Inc | Compositions and methods for modulation of lmna expression |
| PL2735568T3 (pl) | 2006-05-10 | 2018-02-28 | Sarepta Therapeutics, Inc. | Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| WO2009005793A2 (en) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| RU2606627C2 (ru) | 2007-11-15 | 2017-01-10 | Серепта Терапьютикс,Инк. | Способ синтеза морфолиновых олигомеров |
| US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| EP2235034B1 (en) | 2007-12-28 | 2016-11-23 | Sarepta Therapeutics, Inc. | Immunomodulatory agents and methods of use |
| BR122020021379B1 (pt) * | 2008-10-24 | 2021-05-11 | Sarepta Therapeutics, Inc. | oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular |
| DE102009046261B4 (de) | 2009-10-30 | 2012-05-16 | GLOBALFOUNDRIES Dresden Module One Ltd. Liability Company & Co. KG | Verfahren zur Herstellung von Transistoren mit Metallgateelektrodenstrukturen mit großem ε, die vor den Drain/Source-Gebieten auf der Grundlage eines Opferkohlenstoffabstandshalters hergestellt werden |
| EP2499248B1 (en) * | 2009-11-13 | 2017-01-04 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US8012804B1 (en) | 2009-12-23 | 2011-09-06 | Western Digital (Fremont), Llc | Method and system for mounting lasers on energy assisted magnetic recording heads |
| KR20200133284A (ko) | 2010-05-28 | 2020-11-26 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| WO2012115096A1 (ja) | 2011-02-23 | 2012-08-30 | 日本ゼオン株式会社 | 二次電池用負極、二次電池、負極用スラリー組成物及び二次電池用負極の製造方法 |
| CA3092114A1 (en) | 2011-05-05 | 2012-11-08 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| HK1201514A1 (en) | 2011-11-18 | 2015-09-04 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
| ES2935606T3 (es) | 2011-12-08 | 2023-03-08 | Sarepta Therapeutics Inc | Análogos de oligonucleótidos dirigidos a LMNA humana |
-
2012
- 2012-12-07 ES ES18159070T patent/ES2935606T3/es active Active
- 2012-12-07 JP JP2014546150A patent/JP6132848B2/ja active Active
- 2012-12-07 HU HUE12805882A patent/HUE038369T2/hu unknown
- 2012-12-07 LT LTEP12805882.3T patent/LT2788487T/lt unknown
- 2012-12-07 DK DK12805882.3T patent/DK2788487T3/en active
- 2012-12-07 JP JP2014546152A patent/JP6132849B2/ja not_active Expired - Fee Related
- 2012-12-07 HR HRP20181022TT patent/HRP20181022T1/hr unknown
- 2012-12-07 WO PCT/US2012/068606 patent/WO2013086441A2/en not_active Ceased
- 2012-12-07 EP EP12805882.3A patent/EP2788487B1/en active Active
- 2012-12-07 EP EP12806796.4A patent/EP2788488B1/en active Active
- 2012-12-07 SI SI201231334T patent/SI2788487T1/sl unknown
- 2012-12-07 WO PCT/US2012/068609 patent/WO2013086444A2/en not_active Ceased
- 2012-12-07 PT PT128058823T patent/PT2788487T/pt unknown
- 2012-12-07 ES ES12805882.3T patent/ES2674929T3/es active Active
- 2012-12-07 US US13/708,709 patent/US9326992B2/en active Active
- 2012-12-07 EP EP18159070.4A patent/EP3399038B1/en active Active
- 2012-12-07 SM SM20180337T patent/SMT201800337T1/it unknown
- 2012-12-07 US US13/708,708 patent/US9066967B2/en active Active
- 2012-12-07 PL PL12805882T patent/PL2788487T3/pl unknown
- 2012-12-07 TR TR2018/09173T patent/TR201809173T4/tr unknown
- 2012-12-07 RS RS20180774A patent/RS57467B1/sr unknown
-
2015
- 2015-05-11 US US14/709,355 patent/US9682097B2/en active Active
-
2016
- 2016-03-29 US US15/084,255 patent/US9833468B2/en active Active
-
2017
- 2017-03-06 JP JP2017041744A patent/JP6581132B2/ja not_active Expired - Fee Related
- 2017-03-06 JP JP2017041741A patent/JP6596032B2/ja active Active
- 2017-05-15 US US15/595,820 patent/US10076536B2/en active Active
- 2017-10-06 US US15/727,483 patent/US10398721B2/en active Active
-
2018
- 2018-07-03 CY CY20181100698T patent/CY1120495T1/el unknown
-
2019
- 2019-04-16 JP JP2019077698A patent/JP2019129848A/ja active Pending
- 2019-04-17 US US16/387,002 patent/US11071749B2/en active Active
- 2019-06-12 JP JP2019109410A patent/JP2019172691A/ja active Pending
-
2021
- 2021-04-07 JP JP2021065398A patent/JP7277503B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015501817A5 (2) | ||
| JP2015505839A5 (2) | ||
| JP6884250B2 (ja) | ペプチドオリゴヌクレオチドコンジュゲート | |
| US10487326B2 (en) | Peptide oligonucleotide conjugates | |
| JP6596032B2 (ja) | ヒトｌｍｎａを標的とするオリゴヌクレオチド類似体 | |
| CA2799501C (en) | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | |
| ES2929637T3 (es) | Complejo de ácido peptidonucleico que tiene permeabilidad celular mejorada y composición farmacéutica que comprende el mismo | |
| JP2021533804A5 (2) | ||
| JP2014515762A5 (2) | ||
| JP2012506703A5 (2) | ||
| Saleh et al. | Overview of alternative oligonucleotide chemistries for exon skipping | |
| JP2015512254A5 (2) | ||
| CN112996568A (zh) | 用于调节mir-10b活性的微小rna化合物和方法 | |
| JP2018518167A5 (2) |